ImmuSmol Overview
- Founded
-
2012

- Status
-
Private
- Employees
-
10

- Latest Deal Type
-
Grant
- Latest Deal Amount
-
$382K
- Investors
-
3
ImmuSmol General Information
Description
Developer of small molecule antibodies intended to block the mechanisms used by tumors to escape the surveillance of the immune system. The company's antibodies are used in the research, diagnostic and therapeutic applications, helping healthcare professionals in the visualization, quantification, and modulation of monoclonal antibodies interfering with endogenous small molecules involved in cancer and CNS disorders.
Contact Information
Website
www.immusmol.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Discovery Tools (Healthcare)
Diagnostic Equipment
Primary Office
- 229 Cours De L Argonne
- 33000 Bordeaux
- France
+33 05 00 00 00 00
ImmuSmol Valuation & Funding
Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
---|---|---|---|---|---|---|
3. Grant | 01-Apr-2018 | $382K | 00000 | Completed | Generating Revenue | |
2. Early Stage VC | 23-Sep-2014 | 00000 | 00000 | Completed | Generating Revenue | |
1. Accelerator/Incubator | 29-Jul-2014 | $203K | $203K | Completed | Generating Revenue |
ImmuSmol Patents
ImmuSmol Recent Patent Activity
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
GB-201511291-D0 | Agent which increases and/or mimics kynurenine and optional combination thereof with an immunotherapeutic | Inactive | 26-Jun-2015 | ||
AU-2015293833-A2 | Prediction of cancer treatment based on determination of enzymes or metabolites of the kynurenine pathway | Inactive | 24-Jul-2014 | 000000000000 | |
AU-2015293833-A1 | Prediction of cancer treatment based on determination of enzymes or metabolites of the kynurenine pathway | Inactive | 24-Jul-2014 | 000000000000 | |
EP-3172568-A1 | Prediction of cancer treatment based on determination of enzymes or metabolites of the kynurenine pathway | Inactive | 24-Jul-2014 | 000000000000 | |
GB-201413162-D0 | Prediction of cancer treatment based on determination of enzymes or metabolites of the kynurenine pathway | Inactive | 24-Jul-2014 | G01N33/57484 |
ImmuSmol Executive Team (2)
Name | Title | Board Seat | Contact Info |
---|---|---|---|
Alban Bessede Ph.D | Founder & Chief Executive Officer | ||
Loic Cerf | Chief Operating Officer |
ImmuSmol Board Members (1)
Name | Representing | Role | Since |
---|---|---|---|
Vincent Picq | ImmuSmol | Board Member | 000 0000 |
ImmuSmol Signals
ImmuSmol Investors (3)
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
---|---|---|---|---|---|
Eurostars | Government | Minority | 000 0000 | 000000 0 | |
Bpifrance | Sovereign Wealth Fund | Minority | 000 0000 | 000000 0 | |
Incubateur Régional d'Aquitaine | Accelerator/Incubator | Minority | 000 0000 | 000000 0 |